Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H30O2 |
| Molecular Weight | 302.451 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C
InChI
InChIKey=ZDHCJEIGTNNEMY-XGXHKTLJSA-N
InChI=1S/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1
| Molecular Formula | C20H30O2 |
| Molecular Weight | 302.451 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
NORETHANDROLONE, a nandrolone derivative, is a synthetic hormone with anabolic and androgenic properties and moderate progestational activity. It was used to treat, among others, anorexia nervosa, severe burns and trauma, decubitus ulcers, osteoporosis, gastrointestinal diseases. Its list of prescriptions included preparation for and recovery from surgery, bone fracture healing, severe or prolonged illness, and various forms of malnourishment in adults and children. It was withdrawn for the market in most countries in the 1960s, however, it remains viable on the veterinary drug market in Australia.
Originator
Sources: https://anabolic.org/nilevar-norethandrolone/
Curator's Comment: G.D. Searle, LLC is a wholly owned trademark of Pfizer.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Nilevar Approved UseNilevar was prescribed for a variety of illnesses that were benefited by a protein sparing anabolic agent, Listed indications included preparation for and recovery from surgery, severe or prolonged illness, anorexia nervosa, severe burns and trauma, decubitus ulcers, osteoporosis, bone fracture healing, gastrointestinal disease, prolonged corticosteroid administration, and various forms of malnourishment in adults and children. |
Doses
| Dose | Population | Adverse events |
|---|---|---|
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43 years |
Disc. AE: Cholestasis... AEs leading to discontinuation/dose reduction: Cholestasis (grade 5, 1 patient) Sources: |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, 57 years |
Disc. AE: Peliosis hepatis... AEs leading to discontinuation/dose reduction: Peliosis hepatis (grade 5, 1 patient) Sources: |
40 mg 1 times / day steady, oral Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 75 years |
Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice (1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cholestasis | grade 5, 1 patient Disc. AE |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy, 43 years |
| Peliosis hepatis | grade 5, 1 patient Disc. AE |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, 57 years |
| Jaundice | 1 patient Disc. AE |
40 mg 1 times / day steady, oral Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: |
unhealthy, 75 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Restoring arterial pressure with norepinephrine improves muscle tissue oxygenation assessed by near-infrared spectroscopy in severely hypotensive septic patients. | 2010-11 |
|
| Impact of acute psychosocial stress on peripheral blood gene expression pathways in healthy men. | 2009-10 |
|
| Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. | 2009-07 |
|
| Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis. | 2009 |
|
| Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. | 2008-05 |
|
| Wound healing in patients with cancer. | 2008-01-11 |
|
| Evaluation of boldenone formation and related steroids transformations in veal faeces by liquid chromatography/tandem mass spectrometry. | 2008 |
|
| Determination of anabolic steroids in muscle tissue by liquid chromatography-tandem mass spectrometry. | 2007-10-17 |
|
| Factors and markers of growth hormone secretion and gonadal function in Fanconi anemia. | 2007-04 |
|
| [Nosologic discussion between Fanconi disease and congenital dyskeratosis: 1 case of congenital bone marrow aplasia]. | 2006-09 |
|
| Rapid test by liquid chromatography/tandem mass spectrometry to evaluate equine urine reactivity towards 17beta-OH steroids. | 2006 |
|
| Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. | 2005-11 |
|
| Heterogenous changes in neuropeptide Y, norepinephrine and epinephrine concentrations in the hearts of diabetic rats. | 2005-08-31 |
|
| The metabolism of norethandrolone in the horse: characterization of 16-, 20- and 21-oxygenated metabolites by gas chromatography/mass spectrometry. | 2001-02 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:30 GMT 2025
by
admin
on
Mon Mar 31 17:48:30 GMT 2025
|
| Record UNII |
P7W01638W6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LIVERTOX |
NORETHANDROLONE
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
||
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
||
|
WHO-ATC |
A14AA09
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
||
|
WHO-VATC |
QA14AA09
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C80802
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
DTXSID0023379
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
SUB09361MIG
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
200-153-5
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
m8055
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
7513
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
664
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
1961
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
NORETHANDROLONE
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697845
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
DB12787
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
P7W01638W6
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
70581
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
100000083614
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
D009639
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
5858
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY | |||
|
52-78-8
Created by
admin on Mon Mar 31 17:48:30 GMT 2025 , Edited by admin on Mon Mar 31 17:48:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |